Alzheimer’s disease and cytokine IL-10 gene polymorphisms: is there an association?

Carolina Antunes Magalhães; Maria das Graças Carvalho; Lirlândia Pires de Sousa; Paulo Caramelli; Karina Braga Gomes

doi:10.1590/0004-282X20170110

Arquivos de Neuro-Psiquiatria, Table of Contents

CC BY-NC-ND 4.0 · Arq Neuropsiquiatr 2017; 75(09): 649-656
DOI: 10.1590/0004-282X20170110

VIEWS AND REVIEWS

Alzheimer’s disease and cytokine IL-10 gene polymorphisms: is there an association?

A doença de Alzheimer e os polimorfismos no gene da citocina IL-10: há alguma associação?

Authors

Carolina Antunes Magalhães

¹Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil;
Maria das Graças Carvalho

¹Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil;
Lirlândia Pires de Sousa

¹Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil;
Paulo Caramelli

²Universidade Federal de Minas Gerais, Faculdade de Medicina, Departamento de Clínica Médica, Belo Horizonte MG, Brasil.
Karina Braga Gomes

¹Universidade Federal de Minas Gerais, Faculdade de Farmácia, Departamento de Análises Clínicas e Toxicológicas, Belo Horizonte MG, Brasil;

Abstract

ABSTRACT

Alzheimer’s disease (AD) is the most common form of dementia. In the last 15 years, a new theory has proposed the autoimmune mechanism as a trigger for AD. Studies on the association between AD and inflammatory biomarkers have yielded controversial results. Interleukin-10 (IL-10), an anti-inflammatory mediator, has been pointed out as one of the main cytokines associated with the occurrence of AD. Moreover, treatment that increases IL-10 levels could be a potential therapy for AD, since this cytokine acts on amyloid and pro-inflammatory molecule reduction. Based on the current literature, this study reviews evidence regarding the role of IL-10 polymorphisms in the context of AD, which has been shown to be of paramount importance for attenuating neuroinflammation, cognitive dysfunction and neurodegeneration.

RESUMO

A doença de Alzheimer (DA) é a forma mais comum de demência. Nos últimos 15 anos, uma nova teoria propõe um mecanismo autoimmune como o gatilho para a DA. Associações entre DA e biomarcadores inflamatórios têm sido registradas, contudo com resultados controversos. A interleucina-10 (IL-10), um mediador anti-inflamatório, tem sido apontada como uma das principais citocinas associadas com a ocorrência de DA. Além disso, os tratamentos que aumentam os níveis de IL-10 podem ser uma terapia potencial para DA, uma vez que esta citocina atua sobre a redução de substância amiloide e de moléculas pró-inflamatórias. Baseando-se em literaturas atuais, este estudo revisa evidências relacionadas com o papel da IL-10 e seus polimorfismos no contexto da DA, o qual se mostrou ser de fundamental importância para atenuar a neuroinflamação, a disfunção cognitiva e a neurodegeneração.

Alzheimer’s disease - inflammation - Interleukin-10

doença de Alzheimer - inflamação - interleucina-10

Full Text

References

References
1 Alzheimer’s Association. 2015 Alzheimer’s disease facts and figures. Alzheimers Dement. 2015;11(3):332-84. https://doi.org/10.1016/j.jalz.2015.02.003
2 Heppner FL, Ransohoff RM, Becher B.Immune attack: the role of inflammation in Alzheimer disease. Nat Rev Neurosci. 2015;16(6):358-72. https://doi.org/10.1038/nrn3880
3 Nitrini R, Bottino CM, Albala C, Custodio Capuñay NS, Ketzoian C, Llibre Rodriguez JJ et al.Prevalence of dementia in Latin America: a collaborative study of population-based cohorts. Int Psychogeriatr. 2009;21(4):622-30. https://doi.org/10.1017/S1041610209009430
4 Scassellati C, Zanardini R, Squitti R, Bocchio-Chiavetto L, Bonvicini C, Binetti G et al.Promoter haplotypes of interleukin-10 gene and sporadic Alzheimer’s disease. Neurosci Lett. 2004;356(2):119-22. https://doi.org/10.1016/j.neulet.2003.11.033
5 Swardfager W, Lanctçt K, Rothenburg L, Wong A, Cappell J, Herrmann N. A meta-analysis of cytokines in Alzheimer’s disease. Biol Psychiatry. 2010;68(10):930-41. https://doi.org/10.1016/j.biopsych.2010.06.012
6 Rosenberg RN, Lambracht-Washington D, Yu G, Xia W.Genomics of Alzheimer disease: a review. JAMA Neurol. 2016;73(7):867-74. https://doi.org/10.1001/jamaneurol.2016.0301
7 Blach-Olszewska Z, Zaczynska E, Gustaw-Rothenberg K, Avila-Rodrigues M, Barreto GE, Leszek J et al.The innate immunity in Alzheimer disease- relevance to pathogenesis and therapy. Curr Pharm Des. 2015;21(25):3582-8. https://doi.org/10.2174/1381612821666150710144829
8 Dubois RN. The Jeremiah Metzger Lecture: inflammation, immune modulators, and chronic disease. Trans Am Clin Climatol Assoc. 2015;126:230-6.
9 Sardi F, Fassina L, Venturini L, Inguscio M, Guerriero F, Rolfo E et al.Alzheimer’s disease, autoimmunity and inflammation: the good, the bad and the ugly. Autoimmun Rev. 2011;11(2):149-53. https://doi.org/10.1016/j.autrev.2011.09.005
10 Kiyota T, Ingraham KL, Swan RJ, Jacobsen MT, Andrews SJ, Ikezu T.AAV serotype 2/1-mediated gene delivery of anti-inflammatory interleukin-10 enhances neurogenesis and cognitive function in APP+PS1 mice. Gene Ther. 2012;19(7):724-33. https://doi.org/10.1038/gt.2011.126
11 Delaby C, Gabelle A, Blum D, Schraen-Maschke S, Moulinier A, Boulanghien J et al.Central Nervous System and Peripheral Inflammatory Processes in Alzheimer’s Disease: Biomarker Profiling Approach. Front Neurol 2015 Aug;6:181. https://doi.org/10.3389/fneur.2015.00181PMID:26379616
12 Naert G, Rivest S. The role of microglial cell subsets in Alzheimer’s disease. Curr Alzheimer Res. 2011;8(2):151-5. https://doi.org/10.2174/156720511795256035
13 Fuster-Matanzo A, Llorens-Martín M, Hernández F, Avila J.Role of neuroinflammation in adult neurogenesis and Alzheimer disease: therapeutic approaches. Mediators Inflamm. 2013;2013:260925. https://doi.org/10.1155/2013/260925
14 Latta CH, Brothers HM, Wilcock DM. Neuroinflammation in Alzheimer’s disease: a source of heterogeneity and target for personalized therapy. Neuroscience. 2015;302:103-11. https://doi.org/10.1016/j.neuroscience.2014.09.061
15 Steardo L Jr, Bronzuoli MR, Iacomino A, Esposito G, Steardo L, Scuderi C.Does neuroinflammation turn on the flame in Alzheimer’s disease? Focus on astrocytes. Front Neurosci. 2015;9:259. https://doi.org/10.3389/fnins.2015.00259
16 Singhal G, Jaehne EJ, Corrigan F, Toben C, Baune BT.Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci. 2014;8:315. https://doi.org/10.3389/fnins.2014.00315
17 Alam Q, Alam MZ, Mushtaq G, Damanhouri GA, Rasool M, Kamal MA et al.Inflammatory process in Alzheimer’s and Parkinson’s diseases: central role of cytokines. Curr Pharm Des. 2016;22(5):541-8. https://doi.org/10.2174/1381612822666151125000300
18 Saleem M, Herrmann N, Swardfager W, Eisen R, Lanctçt KL.Inflammatory Markers in Mild Cognitive Impairment: A Meta-Analysis. J Alzheimers Dis. 2015;47(3):669-79. https://doi.org/10.3233/JAD-150042
19 Verkhratsky A, Zorec R, Rodríguez JJ, Parpura V. Astroglia dynamics in ageing and Alzheimer’s disease. Curr Opin Pharmacol. 2016;26:74-9. https://doi.org/10.1016/j.coph.2015.09.011
20 Julian A, Dugast E, Ragot S, Krolak-Salmon P, Berrut G, Dantoine T et al.There is no correlation between peripheral inflammation and cognitive status at diagnosis in Alzheimer’s disease. Aging Clin Exp Res. 2015;27(5):589-94. https://doi.org/10.1007/s40520-015-0332-5
21 Sabat R.IL-10 family of cytokines. Cytokine Growth Factor Rev. 2010;21(5):315-24. https://doi.org/10.1016/j.cytogfr.2010.11.001
22 Bagyinszky E, Youn YC, An SS, Kim SY.Characterization of inflammatory biomarkers and candidates for diagnosis of Alzheimer’s disease. Biochip J. 2014;8(3):155-62. https://doi.org/10.1007/s13206-014-8301-1
23 Fiorentino DF, Bond MW, Mosmann TR.Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170(6):2081-95. https://doi.org/10.1084/jem.170.6.2081
24 Acuner-Ozbabacan ES, Engin BH, Guven-Maiorov E, Kuzu G, Muratcioglu S, Baspinar A et al.The structural network of Interleukin-10 and its implications in inflammation and cancer. BMC Genomics. 2014;15 Suppl 4:S2. https://doi.org/10.1186/1471-2164-15-S4-S2
25 Combarros O, Duijn CM, Hammond N, Belbin O, Arias-Vásquez A, Cortina-Borja M et al.Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer’s disease. J Neuroinflammation. 2009;6(1):22. https://doi.org/10.1186/1742-2094-6-22
26 Ma SL, Tang NL, Lam LC, Chiu HF.The association between promoter polymorphism of the interleukin-10 gene and Alzheimer’s disease. Neurobiol Aging. 2005;26(7):1005-10. https://doi.org/10.1016/j.neurobiolaging.2004.08.010
27 Rota E, Bellone G, Rocca P, Bergamasco B, Emanuelli G, Ferrero P. Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer’s disease patients. Neurol Sci. 2006;27(1):33-9. https://doi.org/10.1007/s10072-006-0562-6
28 Richwine AF, Sparkman NL, Dilger RN, Buchanan JB, Johnson RW.Cognitive deficits in interleukin-10-deficient mice after peripheral injection of lipopolysaccharide. Brain Behav Immun. 2009;23(6):794-802. https://doi.org/10.1016/j.bbi.2009.02.020
29 Henderson VW.Estrogen-containing hormone therapy and Alzheimer’s disease risk: understanding discrepant inferences from observational and experimental research. Neuroscience. 2006;138(3):1031-9. https://doi.org/10.1016/j.neuroscience.2005.06.017
30 Ishunina TA, Fischer DF, Swaab DF. Estrogen receptor alpha and its splice variants in the hippocampus in aging and Alzheimer’s disease. Neurobiol Aging. 2007;28(11):1670-81. https://doi.org/10.1016/j.neurobiolaging.2006.07.024
31 Luchetti S, Bossers K, Van de Bilt S, Agrapart V, Morales RR, Frajese GV et al.Neurosteroid biosynthetic pathways changes in prefrontal cortex in Alzheimer’s disease. Neurobiol Aging. 2011;32(11):1964-76. https://doi.org/10.1016/j.neurobiolaging.2009.12.014
32 Cianciulli A, Dragone T, Calvello R, Porro C, Trotta T, Lofrumento DD et al.IL-10 plays a pivotal role in anti-inflammatory effects of resveratrol in activated microglia cells. Int Immunopharmacol. 2015;24(2):369-76. https://doi.org/10.1016/j.intimp.2014.12.035
33 Guillot-Sestier MV, Doty KR, Gate D, Rodriguez J Jr, Leung BP, Rezai-Zadeh K et al.Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology. Neuron 2015;85(3):534-48. https://doi.org/10.1016/j.neuron.2014.12.068
34 Chakrabarty P, Li A, Ceballos-Diaz C, Eddy JA, Funk CC, Moore B et al.IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior. Neuron. 2015;85(3):519-33. https://doi.org/10.1016/j.neuron.2014.11.020
35 Bryson KJ, Lynch MA.Linking T cells to Alzheimer’s disease: from neurodegeneration to neurorepair. Curr Opin Pharmacol. 2016;26:67-73. https://doi.org/10.1016/j.coph.2015.10.003
36 Zheng C, Zhou XW, Wang JZ.The dual roles of cytokines in Alzheimer’s disease: update on interleukins, TNF-α, TGF-β and IFN-γ. Transl Neurodegener. 2016;5(1):7. https://doi.org/10.1186/s40035-016-0054-4
37 Fraga VG, Guimarães HC, Lara VP, Teixeira AL, Barbosa MT, Carvalho MG et al.TGF-β1 Codon 10 T>C polymorphism influences short-term functional and cognitive decline in healthy oldest-old individuals: the Pietà study. J Alzheimers Dis. 2015;48(4):1077-81. https://doi.org/10.3233/JAD-150397
38 Cousin E, Macé S, Rocher C, Dib C, Muzard G, Hannequin D et al.No replication of genetic association between candidate polymorphisms and Alzheimer’s disease. Neurobiol Aging. 2011;32(8):1443-51. https://doi.org/10.1016/j.neurobiolaging.2009.09.004
39 Culpan D, Prince JA, Matthews S, Palmer L, Hughes A, Love S et al.Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer’s disease. Neurosci Lett. 2006;408(2):141-5. https://doi.org/10.1016/j.neulet.2006.08.068
40 Depboylu C, Du Y, Müller U, Kurz A, Zimmer R, Riemenschneider M et al.Lack of association of interleukin-10 promoter region polymorphisms with Alzheimer’s disease. Neurosci Lett. 2003;342(1-2):132-4. https://doi.org/10.1016/S0304-3940(03)00231-3
41 Lio D, Licastro F, Scola L, Chiappelli M, Grimaldi LM, Crivello A et al.Interleukin-10 promoter polymorphism in sporadic Alzheimer’s disease. Genes Immun. 2003;4(3):234-8. https://doi.org/10.1038/sj.gene.6363964
42 Moraes CF, Benedet AL, Souza VC, Lins TC, Camargos EF, Naves JO et al.Cytokine gene polymorphisms and Alzheimer’s disease in Brazil. Neuroimmunomodulation. 2013;20(5):239-46. https://doi.org/10.1159/000350368
43 Arosio B, Trabattoni D, Galimberti L, Bucciarelli P, Fasano F, Calabresi C et al.Interleukin-10 and interleukin-6 gene polymorphisms as risk factors for Alzheimer’s disease. Neurobiol Aging. 2004;25(8):1009-15. https://doi.org/10.1016/j.neurobiolaging.2003.10.009
44 Arosio B, Mastronardi L, Vergani C, Annoni G.Interleukin-10 promoter polymorphism in mild cognitive impairment and in its clinical evolution. Int J Alzheimers Dis. 2010;20:pii 854527. https://doi.org/10.4061/2010/854527.
45 Bagnoli S, Cellini E, Tedde A, Nacmias B, Piacentini S, Bessi V et al.Association of IL10 promoter polymorphism in Italian Alzheimer’s disease. Neurosci Lett. 2007;418(3):262-5. https://doi.org/10.1016/j.neulet.2007.03.030
46 Ma SL, Tang NL, Lam LC, Chiu HF.The association between promoter polymorphism of the interleukin-10 gene and Alzheimer’s disease. Neurobiol Aging. 2005;26(7):1005-10. https://doi.org/10.1016/j.neurobiolaging.2004.08.010
47 Culpan D, Prince JA, Matthews S, Palmer L, Hughes A, Love S et al.Neither sequence variation in the IL-10 gene promoter nor presence of IL-10 protein in the cerebral cortex is associated with Alzheimer’s disease. Neurosci Lett. 2006;408(2):141-5. https://doi.org/10.1016/j.neulet.2006.08.068
48 Ramos EM, Lin MT, Larson EB, Maezawa I, Tseng LH, Edwards KL et al. Tumor necrosis factor alpha and interleukin 10 promoter region polymorphisms and risk of late-onset Alzheimer disease. Arch Neurol. 2006;63(8):1165-9. https://doi.org/10.1001/archneur.63.8.1165
49 Vural P, Değirmencioğlu S, Parildar-Karpuzoğlu H, Doğru-Abbasoğlu S, Hanagasi HA, Karadağ B et al. The combinations of TNFalpha-308 and IL-6 -174 or IL-10 -1082 genes polymorphisms suggest an association with susceptibility to sporadic late-onset Alzheimer’s disease. Acta Neurol Scand. 2009;120(6):396-401. https://doi.org/10.1111/j.1600-0404.2009.01230.x
50 Ribizzi G, Fiordoro S, Barocci S, Ferrari E, Megna M.Cytokine polymorphisms and Alzheimer disease: possible associations. Neurol Sci. 2010;31(3):321-5. https://doi.org/10.1007/s10072-010-0221-9
51 Zhang Y, Zhang J, Tian C, Xiao Y, Li X, He C et al.The -1082G/A polymorphism in IL-10 gene is associated with risk of Alzheimer’s disease: a meta-analysis. J Neurol Sci 2011;303(1-2):133-8. https://doi.org/10.1016/j.jns.2010.12.005
52 Di Bona D, Rizzo C, Bonaventura G, Candore G, Caruso C.Association between interleukin-10 polymorphisms and Alzheimer’s disease: a systematic review and meta-analysis. J Alzheimers Dis. 2012;29(4):751-9. https://doi.org/10.3233/JAD-2012-111838
53 Kang HJ, Kim JM, Kim SW, Shin IS, Park SW, Kim YH et al.Associations of cytokine genes with Alzheimer’s disease and depression in an elderly Korean population. J Neurol Neurosurg Psychiatry. 2015;86(9):1002-7. https://doi.org/10.1136/jnnp-2014-308469
54 Vargas-Alarcón G, Juárez-Cedillo E, Martínez-Rodríguez N, Fragoso JM, García-Hernández N, Juárez-Cedillo T.Association of interleukin-10 polymorphisms with risk factors of Alzheimer’s disease and other dementias (SADEM study). Immunol Lett. 2016;177:47-52. https://doi.org/10.1016/j.imlet.2016.07.011
55 Mun MJ, Kim JH, Choi JY, Jang WC.Genetic polymorphisms of interleukin genes and the risk of Alzheimer’s disease: an update meta-analysis. Meta Gene. 2016;8:1-10. https://doi.org/10.1016/j.mgene.2016.01.001
56 Fraga VG, Guimarães HC, Teixeira AL, Barbosa MT, Carvalho MG, Caramelli P et al.Polymorphisms in cytokine genes influence cognitive and functional performance in a population aged 75 years and above. Int J Geriatr Psychiatry. 2016;2016. https://doi.org/10.1002/gps.4627